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ORIGINAL PAPER
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ABSTRACT
Context: Nigerian soil fungi population is unexplored. It is hypothesized that they harbour new bioactive
chemicals. This hypothesis is based on the large percentage of currently approved medicines that origi-
nated from soil-inhabiting micro-organisms
Objectives: To investigate the antimicrobial and anti-inflammatory properties of Fusarium solani ethyl
acetate (EtOAc) extract selected based on its broad spectrum of antimicrobial potential in an overlay
experiment with seven other soil fungi strains.
Materials and methods: Fungus number 6 (F6), identified by molecular characterization as Fusarium sol-
ani (Mart.) Sacc (Nectriaceae) was selected for studies from eight purified soil fungi due to its superior
broad-spectrum antibiotics producing potential following agar overlay experiment. F6 was fermented for
21d and the minimum inhibitory concentration (MIC) of its EtOAc fermentation extract (dose range:
12.5–100mg/mL) was determined using agar dilution method for Staphylococcus aureus, Bacillus subtilis,
Pseudomonas aeruginosa, Escherichia coli, Salmonella typhi and anti-inflammatory properties determined
using rat-paw (250–500mg/kg) and xylene induced oedema (250–500mg/kg) (in Swiss albino rats and
mice) models, respectively. The ability of the extract to inhibit cyclooxygenase (COX) enzyme was also
determined in vitro using Cayman test kit-760111.
Result: The MIC of the EtOAc extract was <12.5mg/mL for S. aureus, P. aeruginosa and Escherichia coli. It
inhibited xylene induced oedema by 65% compared with 61% observed for diclofenac and was signifi-
cantly (p< 0.05) better than diclofenac in rat-paw-oedema model within the first phase of inflammation.
The extract inhibited COX-1 peroxidase-mediated activities with an IC50 below 5mg/mL.
Conclusions: The extract exhibited strong antibacterial and anti-inflammatory properties, warranting fur-
ther investigations into therapeutic potential of this fungus. This study design can be adapted in soil
fungi metabolomic investigations. We report for the first time the potent anti-inflammatory property of
the ethyl acetate extract of soil strain of F. solani with a possible mechanism of action that involves the
inhibition of COX enzyme.
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Introduction
The serendipitous discovery of penicillin from Penicillium nota-
tum Westling (Trichocomaceae) heralded an era of anti-infective
discovery from microbial sources. With the continuous develop-
ment and emergence of resistant strains of pathogenic organisms,
especially in the Gram-negative organisms that have innate
resistant capabilities (Tillotson 2016), the continuous effort in
new antimicrobial discovery will remain relevant until a lasting
solution is found.
Other pharmacologically important compounds, such as anti-
lipidemic agents were subsequently discovered from microorgan-
isms. Lovastatin, an antilipidemic compound, was isolated from
Aspergillus terreus Thom (Trichocomaceae) (Endo 2010) and its
derivatives have been isolated from A. sclerotiorum Huber
Sp080903f04 (Phainuphong et al. 2016). Actinomycin D, doxo-
rubicin and bleomycin are some other examples of therapeutic
drugs derived from microorganisms currently used in the treat-
ment of cancers (Orlikova et al. 2014).
The effective management of all types of cancer has been an
unmet health need to date. Various approaches to cancer man-
agement have also been adopted by different healthcare systems
worldwide. Recently, a link between inflammation and cancer
progression has been established (Roxburgh and McMillan 2014)
so that compounds with anti-inflammatory properties are pro-
posed to have potential use in cancer treatment and prevention.
It is foreseen that the use of anti-inflammatory agents as adjunct
therapy will be a common approach in cancer management in
clinical practice in the near future (Chan and Detering 2013;
Schafer and Kaschula 2014).
Fusarium solani (Mart.) Sacc (Nectriaceae) is a soil fungus
popularly known for its mycotoxigenic properties (Shi et al.
2017) and as a causative pathogen of skin and nail infections
(Kuruvilla and Dias 2012). Many bioactive compounds have
been reported from the extracts of various Fusarium species
including some potent antibacterial compounds isolated from the
endophytic strain of F. solani (Kyekyeku et al. 2017). Also,
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potent cytotoxic properties against various cancer cell lines and
significant inhibitory activity against Leishmania braziliensis have
been reported for the endophytic strain of F. oxyporum W.C.
Snyder & H.N. Hans (Hyphomycetes) (Nascimento et al. 2012).
In addition, an unrelated investigation of F. oxyporum for bio-
active metabolites resulted in the discovery of antinematodal
constituents within this species (Bogner et al. 2017).
Furthermore, two other bioactive compounds, fusapyrone and
deoxyfusapyrone isolated from the rice culture of Fusarium sem-
itectum Berkeley & Ravenel (Nectriacae) have been found to dis-
play various levels of antimicrobial activities against plant and
human pathogens (Altomare et al. 2000).
In this work, the antimicrobial and anti-inflammatory proper-
ties of Fusarium solani ethyl acetate (EtOAc) extract were inves-
tigated. We report for the first time the potent anti-
inflammatory property of the ethyl acetate extract of soil strain
of F. solani with a possible mechanism of action that involves
the inhibition of cyclooxygenase (COX) enzyme.
Materials and methods
Sample collection
Approximately 100 g of soil was collected aseptically from a spot
around the electric power generating plant in the Faculty of
Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka-
Nigeria in March 2017. A sterile spatula was used to collect the
soil samples from a layer 10 cm below the surface after scraping
the surface. The sample was placed in a sterile sample container
and was immediately taken to the Pharmaceutical Microbiology
& Biotechnology Laboratory where it was analysed.
Isolation and purification of soil fungi
The soil fungi were isolated by the soil dilution technique
described by Waksman (1922). Briefly, the soil sample (1 g) was
suspended in 10mL of double distilled water to make a micro-
bial suspension. Serial dilutions of this suspension (101–105)
were then prepared. Dilutions 102 and 104 were introduced
into different labelled sterile Petri-dishes (triplicate of each dilu-
tion). Molten Malt Extract Agar (MEA) (Oxoid, Basingstoke,
UK), previously sterilized at 121 C, 15 psi for 15min and cooled
to 45 C was added and swirled evenly to ensure the homogen-
eity of the mixture and also to make the colonies discrete.
Chloramphenicol (50mg/L) was added to MEA medium to pre-
vent bacterial growth. The Petri dishes were left to set for 15min
and then incubated at room temperature for 7 d in the dark.
Determination of antibiotic production by the
fungal isolates
A method reported by Chen et al. (2012) was used to determine
the antibiotic production potential of the fungal isolates against
E. coli, Pseudomonas aeruginosa, Bacillus subtilis, Salmonella
typhi, Staphylococcus aureus, A. niger, and C. albicans. The agar
culture of each pure fungal isolate was aseptically cut into a rect-
angular shape and placed on Mueller-Hinton agar previously
inoculated with the different test organisms. This was then incu-
bated at 37 C for 24 h, after which the zone of inhibition of
each test organism from the overlayed fungal agar was measured.
The experiment was carried out in triplicate. (NB: To determine
which fungal culture to study, the antimicrobial sensitivity deter-
mination was carried out using the CLSI prescribed method.)
Identification of fungal cultures
The selected fungus (F6) was identified according to a molecular
biology protocol which includes DNA amplification and
sequencing of the ITS region, described previously by Ebrahim
et al. (2016). The identification was carried out by Dr. Peter Eze,
a pharmaceutical microbiologist of the Institute of
Pharmaceutical Biology, Heinrich Heine University, Dusseldorf,
Germany. The sequence has been deposited in the GenBank with
accession number MG772815.
Fermentation of pure fungal isolate
The solid fermentation medium was prepared by autoclaving
100 g of local rice with 200mL of distilled water in 1 L conical
flask at 121 C for 15min and this was allowed to cool to room
temperature. Thereafter, segments were aseptically cut from the
actively growing pure isolates on MEA and inoculated onto the
fermentation medium contained in 1 L Erlenmeyer flask. This
was properly sealed, and the fermentation process was allowed
for 21 d at 30 C under static conditions.
Extraction of secondary metabolites
The fermentation was stopped with the addition of 500mL of
EtOAc. The solid medium was cut into small sections using a
sterile spatula and the mixture was agitated intermittently for 2 d
and then filtered using Whatman No. 1 filter paper. The filtrate
was concentrated at 40 C under reduced pressure using a rotary
evaporator. The corresponding extract was weighed after evapor-
ation, and the dried fungal extract was stored at 4 C
until needed.
High-performance liquid chromatography (HPLC) analysis
The extract was subjected to HPLC analysis for preliminary dere-
plicative identification of its components. Exactly 1mg/mL of the
extract was prepared in HPLC grade methanol (Sigma Aldrich,
Hamburg, Germany), sonicated for 10min and centrifuged at
3000 rpm for 5min. A 1:5 serial dilution was carried out to
obtain a final concentration of 0.2mg/mL solution and 20 mL of
which was analysed in a Dionex HPLC system equipped with
photodiode array detector (UVD340s, Dionex Softron GmbH,
Germering, Germany) using 125mm Eurosphere-10 C18 prefilled
column (Knauer, Berlin, Germany) with 4mm internal diameter
and 5mm particle size. The mobile phase comprised nano-pure
water adjusted to pH 2 with formic acid and methanol.
Separation was monitored at 254 nm and peaks were identified
by dereplication.
Determination of minimum inhibitory concentrations (MIC)
(agar dilution)
The MIC of the extracts was determined for each of the test
organisms using agar dilution method recommended by Clinical
Laboratory Science Institute (CLSI 2017). Stock solutions of
2mg/mL (2,000mg/mL) of extract were prepared. Then, 2-fold
serial-dilution was carried out to get a range of concentrations
(1000, 500, 250 and 125mg/mL). Thereafter, 10-fold dilution was
obtained for each of the concentrations. Exactly 1mL from each
of these concentrations was transferred into sterile Petri dishes
and 9mL of molten agar cooled to 45 C was added resulting to
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final concentrations of 100, 50, 25 and 12.5 mg/mL, respectively.
The mixture was rocked clockwise and anticlockwise to ensure
proper mixing. Following that, a loopful each of the test organ-
isms previously standardized to McFarland turbidity was
streaked on the solidified agar. A Petri dish containing only
1mL of DMSO (Sigma Aldrich, Hamburg, Germany) mixed with
the sterile molten agar and the organisms were prepared as
above to serve as the negative control. The culture plates were
then incubated at 37 C for 24 h. After incubation, the plates
were examined for visible microbial growth. The plates were
observed for another 7 d.
Experimental animals
The animals (Swiss albino rat and mice) were housed in standard
laboratory conditions of 12 h light, room temperature, and
40–60% relative humidity. They were allowed access to food
(Guinea feeds Nigeria Ltd, Awka, Nigeria) and water. All animal
experiments were conducted in compliance with NIH guide for
care and use of laboratory animals (National Institute of Health
[NIH] (2011) pub No: 85–23), following the protocol approved
by the Ethical Committee on the Use of Animal in Research of
Nnamdi Azikiwe University.
Determination of anti-inflammatory activity using rat paw
oedema model
Anti-inflammatory activity of the ethyl acetate extract was car-
ried out according to the method of Okokon et al. (2012) and
Kim et al. (2017) with slight modification in doses and time. A
total of 168-week old Swiss albino rat models (equal number of
males and females) were grouped into 4 groups of 4 rats per
group. Group 1 received 10mg/kg of distilled water, group 2
received 1.66mg/kg of diclofenac [dose determined using km
factor calculation (Shin et al. 2010)], group 3 received 250mg/kg
of extract, group 4 received 500mg/kg of extract. One hour after
the administration, inflammation was induced by single sub-
plantar injection of 0.1mL raw egg albumin, then inflammation
was checked at 30min, 1, 2, 3 and 4 h post administration for
the paw size. The % inhibition was calculated using the following
formula:
% Inhibition ¼AB
A
 100;
where A ¼ Difference in control (Sterile water group), B ¼
Difference in treatment group.
Anti-inflammatory test using xylene-induced oedema model
A total of 166-week old Swiss albino mice models (equal number
of males and females) were grouped into 4 groups of four ani-
mals each. Group 1 was given equivalent volume of the vehicle
(5% Tween 80) on the posterior part of the left ear. Group II
received 500mg/ear of diclofenac gel. Group III received 250mg/
ear of the extract while group IV received 500mg/ear of the
extract. About 10min after treatment, inflammation was induced
by topical administration of 10 mL of xylene at the anterior part
of the treated ear. Two hours after the induction, the animals
were sacrificed by cervical dislocation. A Cork borer of 6mm
diameter was used to punch out a section of both the treated
and the untreated ears. The weight of each ear was determined
using an analytical weighing balance. Anti-inflammatory activity
was calculated as percentage inhibition of oedema using
the formula:
% Inhibition ¼
Difference in ear weight controlð Þ
 difference in ear weight ðtest substanceÞ
( )
Difference in ear weight ðcontrolÞ  100
Acetic acid-induced writhing experiment
Analgesic activity (stomach writhing) was studied using the
method employed by Ezeja et al. (2011). A total of 16 mice were
used and they were grouped into 4 groups of 4 mice each. The
animals were starved for 12 h prior to the experiment, having
access to drinking water alone. The animals were given the treat-
ment regimen as follows: Group 1 received 10mL/kg of 5%
Tween 80 orally (negative control) whereas group 2 received
15mg/kg diclofenac [dose determined using km factor calcula-
tion (Shin et al. 2010)]. Group 3 was given orally 250mg/kg
extract and group 4 received 500mg/kg extract. After 30min of
administration of the drugs, pain was induced by a single intra-
peritoneal injection of 0.1mL/10 g 1% (v/v) acetic acid. The
number of constrictions (writhes) for each mouse was counted
for 30min commencing from 5min after the intraperitoneal
injection of acetic acid. The percentage writhing inhibition was
calculated using the formula: %Inhibition ¼ CTT  100, where
c¼ number of writhes in negative control group and
T¼ number of writhes in treatment group.
Cyclooxygenase (COX-1 and COX-2) inhibition assay
A stock solution of F. solani fermentation extract was prepared
in methanol as 1mg/mL concentration. Test concentrations of
25, 50 and 100 mg/mL were prepared by serial dilution. The
extract was tested in triplicates using a commercial COX (Ovine)
colourimetric inhibitory screening assay kit following the instruc-
tions recommended by the manufacturer (Cayman test kit-
760111, Cayman Chemical Company, Ann Arbor, MI) (George
et al. 2014). The COX (ovine) inhibitor screening assay measures
the peroxidase activity of COX which is assayed colourimetrically
by monitoring the appearance of N,N,N0,N0-tetramethyl-p-
phenylenediamine. Diclofenac (MW ¼ 296.14) was used as the
positive control for inhibition of COX-1 and COX-2. A mixture
of 10 lL of test extract in 0.1M Tris–HCl pH 8.0 (assay buffer),
150 mL assay buffer, 10 mL Heme and 10mL of enzyme (COX-1or
COX-2) in the inhibitor wells were pre-incubated with the
enzyme at 25 C for 10min prior to the addition of arachidonic
acid (AA). The reaction was initiated by addition of 20 lL of
10mM AA after the addition of 20 mL of colourimetric substrate
and the plate was incubated at 25 C for another 2min. Plate
was read at 590 nm in ELISA plate reader. The reading was
repeated at intervals of 2–5min for over 30min to determine the
reaction rate and the apparent IC50 value.
Statistical analysis
The results were analysed using Microsoft Excel version 2016
and presented as mean± standard error of mean (SEM).
Significance difference between negative control and extract
treated groups were determined using one-way analysis of vari-
ance (ANOVA) at p< 0.05 while post-hoc Turkey test was used
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to determine differences between treatments. Two-way ANOVA
was applied on the COX assay result.
Results
Antibiotic production potential of the fungi isolates
The result of the overlay experiment which was used to deter-
mine which fungi would be selected for identification and further
work is available on request. F6 was selected based on the
observed ‘broad’ spectrum of activity and capability of secreting
substances that inhibited the growth of most of the
test organisms.
Identification of selected fungi isolate
The fungus F6 was identified to be Fusarium solani using a com-
bination of molecular methods that comprised DNA isolation,
PCR amplification, sequencing of the ITS region and nucleotide
sequence blasting carried out in the laboratory of the Institute of
Pharmaceutical Biology, Heinrich Heine University, Dusseldorf,
Germany. The Query cover of the blast was 100% and the identi-
fication was also returned to be 100% certain. The DNA
sequence has been deposited in GenBank and the GenBank
accession number is MG772815.
HPLC analysis of the extract
HPLC analysis of the extract resulted in the detection of 17 dis-
tinct peaks representing at least 17 compounds (Figure 1(a)).
One of the peaks (no. 14) was identified via dereplication to be
enniantin because the database used contained data that matched
its UV spectra. The remaining 16 peaks had no acceptable
matches based on the algorithm of the dereplication software.
The UV spectrum of enniantin are shown in Figure 1(b) and the
structure in Figure 1(c). The HPLC analysis of the extract pro-
vided initial information of the number of compounds in the
extracts that were UV active since the detection was carried out
with Diode Array UV Detector. The enniantin that was identi-
fied was highly conjugated which is one of the characteristics of
compounds that are UV active.
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Figure 1. (a) Chromatogram of Fusarium solani extract at 235 nm. (b) UV spectra of peak 14. (c) Structure of enniantin, a cyclohexadepsipeptide.
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Xylene induced oedema model
The anti-inflammatory potential of the extract was investigated
using xylene model. The ability of the extract to inhibit xylene-
induced inflammation which was comparable to that of diclofe-
nac is shown in Table 1. A dose-dependent inhibition was
observed for the extract and its activity at 500mg/mL was stron-
ger than that of diclofenac for topical application at 250mg/mL,
indicating a potential for use as an anti-inflammatory agent.
Fresh egg albumin induced rat paw oedema model
The anti-inflammatory property of the extract was further inves-
tigated in a rat paw inflammation model using fresh egg albumin
as the phlogistic agent to further establish that the extract has
significant anti-inflammatory potential (Table 2). Similar to the
xylene model, the extract exhibited time-dependent activity that
was significantly better than diclofenac in the first hour espe-
cially at 500 mg/mL. This confirmed the anti-inflammatory activ-
ity of extract and gave more insight as to the kinetics of the
interaction.
Acetic acid-induced stomach writhing
Some compounds that possess anti-inflammatory properties have
been known to have analgesic property which is the case with
non-steroidal anti-inflammatory agents (NSAIDs). Therefore, the
analgesic property of the extract was tested using acetic acid-
induced writhing model to determine the dose of the extract that
was able to inhibit acetic acid-induced writhing compared to
untreated group. As shown in Table 3, the analgesic property of
the extract was found to be inferior compared to diclofenac with
a lower percentage inhibition that was not dose-dependent.
COX-1 and 2 colourimetric inhibition assay
The result of the COX-1 and COX-2 inhibitory assay showed
that the extract had a potent inhibitory activity against COX-1
while it had no activity against COX-2 enzyme. The concentra-
tions of the extract used for the test were within the range rec-
ommended by the manufacturers (30 and 100mg/mL).
Considering the addition of 180mL (150mL buffer, 10 mL Heme
and 20 mL AA, 10 mL enzyme) to the reaction mixture, the final
concentrations of the extract would be divided by 20 which will
give 5mg/mL for an initial dose of 100 mg/mL of the extract and
0.05 mM for diclofenac. The IC50 of the extract against COX-1 is
below 5mg/mL (Table 4). Table 4 shows the percentage inhib-
ition values for COX-1 activities at different time points for the
extract at different doses. The positive control and the extract at
5 mg/mL were also represented graphically (Figure 2).
Determination of MIC of the extract against test organisms
The MIC of the extract against selected test pathogens was deter-
mined. The result shows that the extract showed MIC <12.5mg/
mL for S. aureus, E. coli and P. aeruginosa whereas it showed
higher MICs for other organisms tested. This indicates that the
extract also has reasonable antibacterial property.
Discussion
The results of the different tests carried out on the ethyl acetate
fermentation extract of F. solani showed that it possesses potent
antibacterial and anti-inflammatory properties. In addition, the
extract strongly inhibited COX-1 enzyme in in vitro experiment.
The antimicrobial property of the extract was profound
against P. aeruginosa, E. coli and S. aureus. The MICs of the
extract against these organisms were below 12.5 mg/mL while the
MICs for B. subtilis and S. typhi were 25 and 100mg/mL, respect-
ively, indicating a broad range of activity against both Gram-
positive and Gram-negative organisms. Although the MIC of the
extract against S. typhi, one of the three Gram-negative organ-
isms, was 100mg/mL, considering that Gram-negative organisms
have innate resistance capability because of the characteristic
Table 1. The anti-inflammatory activity of Fusarium solani extracts in vivo using
xylene model.
Treatment
Mean ear
weight (mg)
(left ear) ± SEM
Mean ear
weight (mg)
(right ear) ± SEM %Inhibition
Extract 250 mg 15.2 ± 2.12 10.8 ± 0.20 19.0134
500 mg 15.7 ± 1.8 13.8 ± 0.18 65.635
Diclofenac 500 mg 20.0 ± 0.5172 8.9 ± 0.39 61.807
10 mL of ethanol 18.2 ± 1.22 12.8 ± 1.35 0
Not significantly different from the positive control.
Table 2. The %inhibition of egg albumin-induced rat paw oedema by F. solani extract.
Test samples Dosage
%Inhibition of oedema formation with time
30min 1 h 2 h 3 h 4 h
Control 10mL/kg distilled water 0 0 0 0 0
Diclofenac 1.66mg/kg diclofenac 9 8 36 57.45 85
F6 Extract 250mg/kg 0 0 21.91 7.4 1.14
500mg/kg 16.59 14.89 39.36 21.91 24.54
Significantly different from the positive control.
Table 4. Time-dependent inhibition (%) of COX-1 enzyme activity by F. solani
extract in vitro.
Percentage inhibition/time
Time (min) 1 2 3 5 6 7 8 10 12 17 22 27 32
F6 25 lg 8 9 9 9 9 10 9 9 9 10 10 10 9
50lg 36 34 29 27 26 26 25 24 23 23 21 19 18
100lg 69 81 82 83 83 84 85 86 87 92 95 100 104
Diclofenac 1 mM 22 20 19 19 17 17 16 15 14 14 12 12 11
Significantly different from the positive control for all figures in the row.
Table 3. Analgesic effect of F. solani extracts on the acetic acid-induced writh-
ing in mice.
Test samples Dosage
Mean number of
writhings ± SEM
%Inhibition
of writhings
Tween 80 10mL/kg 33.67 ± 4.33 0
Diclofenac 15mg/kg 9.33 ± 4.98 72.29
F6 Extract 250mg/kg 17.0 ± 6.66 49.51
500mg/kg 24.67 ± 8.51 26.73
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nature of their cell membrane, this result is of significant interest
and importance. The extract appeared to have predominantly
oily texture; therefore, it could be that its oily nature facilitates
its passage or interaction with the hydrophobic cell membrane of
the Gram-negative organisms. It is worthwhile to mention that
no new growth was observed on the plates even after 7 d of fur-
ther incubation suggesting that the observed absence of growth
was due to bactericidal activity of the extract rather than bac-
teriostatic activity. Our result agrees with the report by Kyekyeku
et al. (2017) on the antibacterial activity of F. solani extract and
compounds suggesting that the Gram-negative bacteria are very
susceptible to Fusarium solani metabolites.
The anti-inflammatory property of the extract was also eval-
uated using two established inflammation models. The xylene-
induced ear oedema model was used to evaluate the ability of
the extract to inhibit topically induced acute inflammation while
the rat paw oedema model was used to study its activity against
systemically induced inflammation. Topical application of xylene
instantly results in the increase in vascular permeability as a
response to the irritation caused by the chemical. The increased
vascular permeability allows the infiltration of fluid and protein
into the extravascular area resulting in oedema which is a char-
acteristic of acute inflammation (Atta and Alkohafi 1998; Ono
et al. 2017). Although the extract (500 mg/mL) was able to inhibit
this process by 65% compared to the 61% observed for the posi-
tive control, diclofenac (500mg/mL), there was no significant dif-
ference p< 0.05 between their effects. There was, however, a
significant difference between the effects of the extract at 500mg/
mL compared to its effect at 250 mg/mL. This suggests that the
extract has the ability to inhibit acute inflammation in a dose-
dependent manner. Oedema model induced by xylene has been
widely used for estimating the anti-inflammatory properties of
potential drug candidates because of its excellent predictive val-
ues (Ma et al. 2013; Sowemimo et al. 2013).
The dose range of the extract determined from the xylene
model was applied for the egg albumin model. Inflammation
induced by egg albumin is reported to be biphasic. The first
phase that occurs within 2 h of inflammation involves the release
of histamine and serotonin that results in an increased vascular
permeability whereas the second phase is mediated by the pros-
taglandins, the kinins and the lysosomes (Anosike et al. 2012;
Ma et al. 2013). The effect of the extract at 250mg/kg was not
significantly (p< 0.05) better than that of the negative control
against the development of inflammation for the first 1 h.
However, the anti-inflammatory activity of the extract at this
dose reflected afterwards as could be seen in the percentage
inhibition of oedema formation which peaked after 2 h. After
that, the percentage of inhibition decreased with time. At
500mg/kg, the extract demonstrated a rapid onset of inhibition
of oedema formation significantly (p< 0.05) better than the
effect of the positive control, diclofenac (Table 4). Similar to the
effect observed at 250mg/kg, the effect of the extract at 500mg/
kg peaked at 2 h and afterwards reduced with time. The extract
at 500mg/kg was significantly (p< 0.05) better than at 250mg/
kg as well as the negative control which confirms its dose-
dependent activity as was observed for the xylene model. The
early onset of action suggests that this extract could be very use-
ful for acute inflammation and if in combination with an agent
whose activity peaks in the second phase, for example diclofenac,
could potentiate its effect in the management of inflammatory
processes. It has been reported that NSAIDs do not effectively
inhibit the first phase of inflammation (Salvemini et al. 1996).
This explains the reason why the percentage inhibition observed
for diclofenac within the first 1 h was in single digits. The
reduced activity in the second phase for the extract also suggests
that the extract may have little or no direct effect on COX site
reaction, especially for COX-2 isoform, whose upregulation leads
to the recruitment and production of inflammatory mediators,
the presence of which characterize the second (cellular) phase of
inflammation (Ricciotti and Fitzgerald 2011). Rat paw oedema
model is reliable and of good value in studying the contribution
of inflammatory mediators in inflammatory response (Salvemini
et al. 1996), therefore, it is widely used in the estimation of the
anti-inflammatory potential of new drug candidates (Karakus
et al. 2013; Cong et al. 2015).
Inflammatory mediators and consequently inflammation
have been linked with pain (Dubin and Patapoutian 2010;
Ronchetti et al. 2017). Often, compounds with anti-
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Figure 2. Time-dependent inhibition of COX-1 enzyme by F. solani extract.
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inflammatory activities alleviate pain. The extract was tested for
its ability to modulate pain perception using the acetic acid-
induced abdominal constriction model. The extract showed cer-
tain level of analgesic properties which, however, was not dose
dependent within the dose range tested (Table 3). The observed
analgesic property which was estimated based on the ability of
the agent to inhibit abdominal constriction induced by acetic
acid at 250mg/kg was about 2/3 of the effect achieved by the
positive control, diclofenac at 15mg/kg. This result which is
significantly better than the negative control (p< 0.05) deserves
further consideration.
The mechanism of anti-inflammatory action was investigated
in vitro to determine if the extract has any activity against
COX enzyme isoforms 1 and 2. The rate of reaction between
the enzyme and the extract was monitored for over 30min. It
was found that the extract at the dose of 5 mg/mL inhibited
69% of the enzyme activity after 2min. The inhibition
increased with time and reached 100% before 30min. On the
other hand, the positive control at the final dose of 0.05 mM
exhibited an initial enzyme inhibition of 22% which was
slightly decreased towards the end of the 30min period. The
effect of the extract was significantly better than that of the
positive control at p< 0.05. NSAIDs are known to bind slowly,
competitively and reversibly to COX enzyme (Meek et al. 2010)
and as a result, their inhibition of the enzyme is not main-
tained for a long period of time. This could explain the reduc-
tion in the inhibition percentage of the enzyme with time.
Also, classical NSAIDs preferentially target the COX reactions
rather than the peroxidase reaction (Szewczuk et al. 2004;
Bettelheim et al. 2012) . On the other hand, neither the extract
nor the positive control had an inhibitory effect on COX-2 in
this investigation. Because classical NSAIDs do not significantly
inhibit peroxidase reactions (Bettelheim et al. 2012), the inhib-
ition percentage observed for diclofenac (the positive control)
in this peroxidase-based assay was justified. Some compounds,
such as resveratrol known to inhibit both isoforms of COX
have been reported to have weak effect on the peroxidase activ-
ity of COX-2 (Szewczuk et al. 2004). The inhibition of COX-1
catalytic activity is desirable in the prevention of cardiovascular
conditions. The lack of inhibition of COX-2 enzyme activity by
the extract further explains the reason for the reduced activity
in the second phase of inflammation in rat paw
oedema experiment.
The HPLC analysis of the extract and dereplication revealed
one known compound, enniantin, a cyclic depsipeptide known
to have antibiotic property (Zaher et al. 2015) which could
have contributed to the profound antibiotic property observed.
Although the antibacterial properties of endophytic strain of F.
solani extracts and some compounds have been reported
(Kyekyeku et al. 2017), we were able to demonstrate and pro-
vide the experimental evidence that the antibacterial property
could be bactericidal. It could also be possible that the range of
secondary metabolites from the two strains may differ even
though both originated from West African countries of Ghana
and Nigeria, respectively. Also, while our source was the soil
around a power generating plant house, which is considered to
be a stress area, the other was an endophyte from a plant part
collected from the forest. The differences pointed out could
have generated different types of metabolic pathways suitable
for survival in their respective environments. It is possible that
the antibacterial properties are not mediated by the
same compounds.
Conclusions
In addition to the antimicrobial properties of the Fusarium sol-
ani extract, we are also reporting for the first time that the anti-
inflammatory property is concomitantly present. Different in
vivo models of inflammation were used to study the anti-inflam-
matory potentials of the extract and all suggested that the extract
possesses strong anti-inflammatory property especially at the first
phase of inflammation. Our findings also suggested that the
extract does not inhibit COX-2 activity but in combination with
other NSAIDs could result in a potent arsenal against inflamma-
tory conditions. The extract also exhibited profound antibacterial
activity against Gram-negative organisms used in the test. A
combination of antimicrobial and anti-inflammatory property in
a single extract can find many applications in the pharmaceut-
ical industry.
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